Sorbello, V., Ciprandi, G., Di Stefano, A., Massaglia, G.M., Favata, G., Conticello, S., Malerba, M., Folkerts, G., Profita, M., Rolla, G., et al. (2015) Nasal IL-17F Is Related to Bronchial IL-17F/Neutrophilia and Exacerbations in Stable Atopic Severe Asthma. Allergy, 70, 236-240.
https://doi.org/10.1111/all.12547

has been cited by the following article:

• TITLE: Silencing of ERK2 with Small Interference RNA Regulates the Expression of CXCL1 in Th17 Cell

  AUTHORS: Wei Wu, Qian Zhang, Kaixia Cai, Dan Wang, Hui Chen

  KEYWORDS: Asthma, Th17 Cells and ERK2

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.9 No.7, July 22, 2021

  ABSTRACT: Patients with steroid-resistant asthma had their monocyte-derived TH17 cells collected. The expression levels of ERK2 in the TH17 were silenced and inhibited using ERK2 specific small interfering RNA (siRNA). By screening of CXCL1 and IL-17A in the TH17 culture supernatant, the expression levels of ERK2 and CXCL1 were determined. Using targeted siRNA to inhibit ERK2, the expression of ERK2 in the TH17 was reduced. Furthermore, inhibiting ERK2 hindered CXCL1 expression and decreased CXCL1 and IL-17A production. These findings suggest that ERK2 is involved in the synthesis of CXCL1 and IL-17A, two proteins that play a key role in the pathogenesis of hormone-resistant asthma.